Xin Gao, MD, on Advanced or Metastatic Urothelial Carcinoma: LY4101174
ASCO 2026
Xin Gao, MD, of Massachusetts General Hospital and Harvard Medical School, discusses initial results from the phase I EXCEED trial of LY4101174, a Nectin-4–targeting antibody-drug conjugate, for patients with advanced or metastatic urothelial carcinoma (Abstract 4517).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
This is a clinical trial that was performed as a dose-escalation study in patients with advanced metastatic urothelial carcinoma as well as other solid tumors known to express Nectin-4. The background for this study is that we know that enfortumab vedotin and pembrolizumab have really revolutionized the treatment for patients with advanced and metastatic urothelial cancers. But unfortunately, treatment resistance and treatment intolerability become an issue. Patients do need additional treatments beyond EV plus pembrolizumab, and unfortunately, at this time, the standard of care remains unclear and prognosis remains poor for patients who need another therapy beyond EV and pembrolizumab. We conducted this phase 1 clinical trial with a dose-escalation design. Eighty-six patients in total had metastatic urothelial cancers, and we looked at various dose levels, starting with low doses, Q2-week dosing as well as Q3-week dosing, which was explored after patients developed DLTs at the third dose level of Q2-week dosing. The vast majority of patients were heavily pretreated patients. Median lines of prior therapy was 3; 88% of patients had received prior platinum-based chemotherapy, 92% had received prior enfortumab vedotin, and all patients had received prior immune checkpoint inhibitors. So I think this was a study that really captured, you know, what's going on in the real world when patients need to think about another therapy beyond EV plus pembrolizumab and platinum-based chemotherapy. What we saw was that there was antitumor activity, particularly at the highest dose level of 4 mg/kg Q3-week dosing. We saw an objective response rate of 36% with the dose, with a disease control rate of 76%. However, we also ran into dose-limiting and significant hematologic toxicities, including grade 3 or higher anemia, neutropenia, thrombocytopenia, as well as febrile neutropenia at the highest dose level despite use of G-CSF prophylaxis. So the EXCEED study was a proof of concept that further targeting of Nectin-4 remains a viable and important clinical strategy for patients with treatment-refractory metastatic urothelial cancers after enfortumab vedotin. I think future work will be needed to continue to develop and study newer, other kinds of Nectin-4-targeting drugs with different payloads, different linkers, that hopefully will be able to find a dose that's both efficacious and tolerable for patients.
The ASCO Post Staff
Sanjay Popat, PhD, FRCP, of the Royal Marsden Hospital & Institute of Cancer Research, talks about the findings of the phase III AcceleRET-Lung study, which looked at the oral tyrosine kinase inhibitor pralsetinib as first-line therapy for patients with RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC) (Abstract 8504).
Paolo Tarantino, MD, PhD, of Dana-Farber Cancer Institute, reviews the results of a large clinicogenomic database study that looked at overall survival by genomic profile among patients with HER2-positive metastatic breast cancer. Patients with mutations in key DNA repair genes experienced a numerically worse prognosis, representing an unmet need for drug development, say researchers (Abstract 1045).
Lucy Gilbert, MD, of McGill University Health Centre, discusses subgroup analyses from the ROSELLA study. Relacorilant plus nab-paclitaxel demonstrated a statistically and clinically significant overall survival benefit in patients with platinum-resistant ovarian cancer compared to a weekly taxane; subgroup analyses for overall survival showed a consistent benefit favoring the addition of relacorilant to nab-paclitaxel irrespective of prior taxane use (Abstract 5503).
Jennifer A. Woyach, MD, of The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University, discusses the ongoing, actively recruiting ROCKET-CLL trial, which is a phase III study aiming to compare the efficacy of rocbrutinib vs pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have been pretreated with Bruton tyrosine kinase covalent inhibitors (Abstract TPS7100).
For more information about the trial, visit ClinicalTrials.gov (identifier NCT07342478).
The ASCO Post Staff
Mark A. Dickson, MD, of Memorial Sloan Kettering Cancer Center, presents findings from SARC041, a phase III randomized double-blind study of abemaciclib vs placebo in patients with dedifferentiated liposarcoma; patients who received abemaciclib experienced a statistically significant improvement in progression-free survival (Abstract LBA2).